NCX 470 Shows Dual Mechanism for IOP Reduction in Glaucoma Studies | Healio

New data presented at the American Glaucoma Society meeting this week offer further support for the potential benefits of NCX 470, a nitric oxide-donating bimatoprost eye drop, in managing glaucoma. Three studies highlighted the drug’s ability to lower intraocular pressure (IOP) through multiple mechanisms, suggesting it could become a valuable addition to the treatment landscape for this common cause of vision loss.

Understanding NCX 470 and its Mechanism

Glaucoma encompasses a group of eye diseases that damage the optic nerve, often due to elevated IOP. Current treatments primarily focus on lowering IOP, but NCX 470 offers a potentially novel approach. Unlike traditional IOP-lowering medications, NCX 470 releases nitric oxide, a molecule known to play a role in blood vessel health and ocular fluid dynamics. This dual action – combining the IOP-lowering effects of bimatoprost with the potential benefits of nitric oxide – is what sets it apart.

The phase 3 DENALI trial, led by Sanjay G. Asrani, MD, compared NCX 470 to latanoprost, a commonly prescribed glaucoma medication, in 696 patients. Results, previously reported by Healio, demonstrated non-inferiority in IOP reduction. Notably, NCX 470 showed greater IOP reduction during afternoon assessments at weeks 2 and 6, with efficacy sustained for at least three months. Asrani emphasized the drug’s safety and tolerability, with discontinuation rates comparable between the two groups.

Dual Pathways to Lowering IOP

Further investigation into how NCX 470 lowers IOP came from a phase 3b clinical trial conducted by Arthur J. Sit, SM, MD, and colleagues. This study, involving 18 healthy adults, examined the drug’s impact on aqueous humor dynamics – the fluid circulation within the eye. Researchers assessed aqueous flow rate, outflow facility, and uveoscleral outflow, a less conventional pathway for fluid drainage.

The findings revealed that NCX 470 significantly improved outflow facility, increasing from a baseline of 0.283 µL/min/mm Hg to 0.332 µL/min/mm Hg by day 8. This increase accounted for 42% of the observed IOP reduction. Importantly, the drug also boosted uveoscleral outflow, improving from -0.12 µL/min to 0.44 µL/min over the same period, contributing to 58% of the IOP reduction. Details of the trial design are available online. This suggests NCX 470 works by enhancing both the conventional trabecular meshwork pathway and the alternative uveoscleral pathway for fluid drainage.

Subgroup Analysis Confirms Benefits

A subgroup analysis from the DENALI trial, presented by Jason Bacharach, MD, focused on 549 U.S. Patients. This analysis showed consistent IOP reduction with NCX 470 across all time points, ranging from 8.1 mm Hg to 10.1 mm Hg. The latanoprost group experienced reductions between 7.3 mm Hg, and 9.9 mm Hg. NCX 470 demonstrated statistically significant IOP reduction at week 2 (both 8 a.m. And 4 p.m.) and week 6 (4 p.m.).

What Does This Mean for Patients?

These findings are encouraging for individuals with glaucoma or ocular hypertension. While existing treatments are effective for many, some patients may not respond adequately or may experience side effects. NCX 470’s novel mechanism of action could offer a new option for these individuals. The dual pathway approach may also be particularly beneficial in certain types of glaucoma where specific outflow pathways are more affected. However, it’s crucial to remember that these are still study results, and NCX 470 is not yet widely available.

It’s important to understand that IOP reduction is just one aspect of glaucoma management. Regular eye exams, adherence to prescribed medications, and lifestyle modifications are all essential components of a comprehensive treatment plan. Patients should always discuss their treatment options with a qualified ophthalmologist to determine the best course of action for their individual needs. The American Academy of Ophthalmology provides comprehensive information on glaucoma for patients and caregivers.

The Role of Nitric Oxide in Glaucoma

The inclusion of nitric oxide in NCX 470 is based on growing research into its potential protective effects on the optic nerve. Nitric oxide is a signaling molecule involved in various physiological processes, including blood vessel dilation and neuroprotection. Some studies suggest that nitric oxide deficiency may contribute to the development and progression of glaucoma. By delivering nitric oxide directly to the eye, NCX 470 aims to enhance ocular blood flow and protect retinal ganglion cells, the neurons that transmit visual information from the eye to the brain.

What’s Next for NCX 470?

Doug Hubatsch, chief scientific officer at Nicox, highlighted the potential for NCX 470 to address an unmet need in glaucoma treatment. The company believes the drug’s robust IOP-lowering effect and favorable safety profile, combined with its unique mechanism of action, could make it a valuable addition to the therapeutic arsenal.

Nicox has indicated that preclinical data suggest potential benefits in retinal protection, which could have implications for slowing the progression of glaucoma. The company is continuing to analyze the data from the DENALI trial and other studies to further refine our understanding of NCX 470’s efficacy and safety. The next steps involve submitting the data to regulatory authorities for potential approval, a process that typically involves a thorough review of the clinical trial results and manufacturing processes. Further research will likely focus on identifying which patient populations are most likely to benefit from NCX 470 and exploring its potential in combination with other glaucoma medications. A press release detailing the AGS presentations is available on the Nicox website.